The COG SDC consists of experienced Ph.D. level statisticians located at major universities directing the statistical analysis of COG data. In addition to this strong core of professionals, COG data are collected, managed and archived at one location: the COG Research Data Center at the University of Florida in Gainesville FL. This model combines the experience of professional statisticians, some of who have worked in pediatric oncology for more than 20 years, with a data management center with a long history of service to the pediatric research community. This model provides significant advantages to the research agenda of COG. The statistical leadership is comprised of individuals with significant experience in the design and analysis of clinical trials. Data are collected at a single site using uniform conventions and overseen by individuals with years of experience in this area. This makes data collection more efficient for institutional investigators and promotes the aggregation of large databases representing years of clinical trials work. The major goals of the SDC are: (1) participate in setting Group scientific priorities in specific disease areas through membership on strategy groups, tasks forces, and discipline committees; (2) evaluate COG therapeutic, epidemiologic, and biologic studies that are proposed or in development, to ensure the stated study aims can be accomplished (3) provide a study design, data acquisition plan and study analysis plan that ensures the study aims will be addressed correctly and efficiently, with appropriate monitoring of patient safety. (4) Perform statistical analyses of data relevant to interim monitoring and final reporting of the results of COG studies; (5) ensure that the needs of COG studies for data collection, computerization, report generation, committee review, safety monitoring, data quality control and institutional performance are met; (6) Investigate and test current information technology tools and adopt those that provide the most efficient means of quality data collection; (7) Establish policies for study conduct that ensure appropriate evaluation of study questions; (8) develop or extend statistical methodology to address unique problems arising in Group investigations; and (9) Provide training in the statistical aspects of the Group's scientific endeavors to various members of COG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA098413-03
Application #
6892383
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2003-06-20
Project End
2006-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
3
Fiscal Year
2005
Total Cost
$5,979,365
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Mullen, Elizabeth A; Chi, Yueh-Yun; Hibbitts, Emily et al. (2018) Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol :JCO1800076
Laetsch, Theodore W; Roy, Angshumoy; Xu, Lin et al. (2018) Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clin Cancer Res 24:3888-3897
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Marks, Lianna J; Pei, Qinglin; Bush, Rizvan et al. (2018) Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:e27375
Hawkins, Douglas S; Chi, Yueh-Yun; Anderson, James R et al. (2018) Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol 36:2770-2777
Burns, Melissa A; Liao, Zi Wei; Yamagata, Natsuko et al. (2018) Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia 32:2126-2137
Bolouri, Hamid; Farrar, Jason E; Triche Jr, Timothy et al. (2018) The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24:103-112
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Alexander, Thomas B; Gu, Zhaohui; Iacobucci, Ilaria et al. (2018) The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562:373-379
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570

Showing the most recent 10 out of 473 publications